Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | BLVRB | P30043 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | RARA | P10276 | 4/20 | 0.42 |
| ▸ | RARB | P10826 | 4/20 | 0.42 |
| ▸ | RARG | P13631 | 4/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.40 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384837 | 0.90 | NR1H4 (0.52) | NR1H4MAOABLVRBHDAC6RARA | |
| SCHEMBL389806 | 0.89 | NR1H4 (0.55) | NR1H4MAOABLVRBHDAC6GRM5 | |
| SCHEMBL387937 | 0.85 | NR1H4 (0.59) | NR1H4MAOABLVRBHDAC6S1PR1 | |
| SCHEMBL388073 | 0.84 | NR1H4 (0.54) | NR1H4MAOABLVRBHDAC6RARA | |
| SCHEMBL388121 | 0.84 | S1PR1 (0.52) | NR1H4S1PR1CHUKTXNRD1NOX4 | |
| SCHEMBL389684 | 0.83 | NR1H4 (0.53) | NR1H4MAOABLVRBHDAC6RARA | |
| SCHEMBL388747 | 0.83 | NR1H4 (0.60) | NR1H4MAOABLVRBHDAC6S1PR1 | |
| SCHEMBL389932 | 0.82 | MAOA (0.50) | MAOABLVRBHDAC6RARARARB | |
| SCHEMBL389070 | 0.82 | RARA (0.51) | MAOABLVRBHDAC6RARARARB | |
| SCHEMBL388070 | 0.82 | NR1H4 (0.52) | NR1H4RARARARBRARGS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691511-B2 | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and their use in bioassays | PTC THERAPEUTICS, INC. (US) | 2014-04-08 | — | — | US | claimed |
| EP-2068871-B1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | claimed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | claimed |
| EP-2068871-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC Therapeutics, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2008130370-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | claimed |
| US-8691511-B2 | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and their use in bioassays | PTC THERAPEUTICS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2068871-B1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101641-B2 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2068871-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC Therapeutics, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008130370-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130370-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THE USE FOR NONSENSE SUPPRESSION | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139632-A1 | Such as 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-2-hydroxybenzoic acid for modulating premature translation termination or nonsense-mediated mRNA decay in cells | UPF1, RIOX2, RNMT | NR1H4 2941/4885MAOA 2396/4885BLVRB 2036/4885 |
| US-20120087896-A1 | HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS | UPF1, RIOX2, RNGTT | NR1H4 1404/4885MAOA 1591/4885BLVRB 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.